These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11673194)

  • 1. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.
    Burman WJ; Reves RR
    Am J Respir Crit Care Med; 2001 Oct; 164(7):1112-3. PubMed ID: 11673194
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
    Kunimoto D; Warman A; Beckon A; Doering D; Melenka L
    Clin Infect Dis; 2003 Jun; 36(12):e158-61. PubMed ID: 12802781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    JAMA; 2002 Dec; 288(23):2967. PubMed ID: 12492097
    [No Abstract]   [Full Text] [Related]  

  • 4. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
    [No Abstract]   [Full Text] [Related]  

  • 5. From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    JAMA; 2001 May 23-30; 285(20):2572-3. PubMed ID: 11396466
    [No Abstract]   [Full Text] [Related]  

  • 6. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
    Potolidis E; Mantadakis E; Zeniodi MH; Samonis G
    Scand J Infect Dis; 2005; 37(2):155-7. PubMed ID: 15773037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection.
    Castro KG; Jereb JA; Koppaka VR; Cohn DL
    Chest; 2003 Mar; 123(3):967. PubMed ID: 12628913
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
    Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
    Jasmer RM; Daley CL
    Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
    [No Abstract]   [Full Text] [Related]  

  • 11. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
    McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
    Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
    Vu D; Macdonald L
    CMAJ; 2001 Oct; 165(7):942-3, 946-7. PubMed ID: 11599338
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatotoxicity after a short course of low-dose pyrazinamide.
    al Sarraf KA; Michielsen PP; Hauben EI; Lefebure A; Ramon AM; Van Marck EA; Pelckmans PA
    Acta Gastroenterol Belg; 1996; 59(4):251-3. PubMed ID: 9085628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antituberculosis drugs and hepatotoxicity.
    Sharma SK
    Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinically apparent liver damage during brief tuberculosis therapy].
    Estay S; Armas Merino R; Vega C; Soto JR
    Rev Med Chil; 1981 Oct; 109(10):941-4. PubMed ID: 7344017
    [No Abstract]   [Full Text] [Related]  

  • 17. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
    Cook PP
    Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
    [No Abstract]   [Full Text] [Related]  

  • 18. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.
    ;
    MMWR Morb Mortal Wkly Rep; 2003 Aug; 52(31):735-9. PubMed ID: 12904741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
    van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
    Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Ijaz K; McElroy PD; Navin TR
    Clin Infect Dis; 2004 Jul; 39(2):289. PubMed ID: 15307044
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.